← Leaderboards
Lawrence S Kegeles
Columbia University Health Sciences
$3,044,400
Attributed
$6,476,686
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $849.7K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,476,686 · 6
By mechanism
R01$5,169,667 · 2
K08$849,768 · 1
R21$454,617 · 1
M01$2,634 · 2
Top collaborators
- Ragy Ramsis Girgis9 shared
- Dikoma C. Shungu5 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Virginia A Rauh$10,885,143
- Dikoma C. Shungu$12,054,848
- Michael T Compton$12,324,780
- Amy Margolis$11,079,492
- Stephanie Rolin$1,014,692
Others in their field
Top investigators on “Schizophrenia”
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$104,668,216
- Raquel E Gur · University Of Pennsylvania$60,189,770
- Mark J Daly · Broad Institute, Inc.$48,989,393
- John M Kane · Long Island Jewish Medical Center$45,235,871
- Carrie E Bearden · University Of California Los Angeles$42,025,230
- Scott W Woods · Yale University$41,221,536
Research focus
SchizophreniaNeurochemistryDopamineBiological MarkersPharmaceutical PreparationsSymptomsReportingAntipsychotic AgentsBrainMagnetic Resonance ImagingPrefrontal CortexBaseSitePositron Emission TomographyMedialHuman SubjectMagnetic Resonance SpectroscopyClinical ResearchGamma AminobutyrateBioimaging /Biomedical ImagingFutureLeadGlutamatesResearch Personnel
Grant awards (16)
A Multimodal Imaging Study of Dopamine in Early Psychosis$706,228
R01 · FY2023 · MH
A Multimodal Imaging Study of Dopamine in Early Psychosis$742,572
R01 · FY2022 · MH
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia$686,941
R01 · FY2021 · MH
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia$696,494
R01 · FY2020 · MH
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia$707,540
R01 · FY2019 · MH
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia$780,214
R01 · FY2018 · MH
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia$849,678
R01 · FY2017 · MH
Neurochemical and Clinical Effects of Glutamate Modulation in Schizophrenia$239,841
R21 · FY2015 · MH · contact PI
Neurochemical and Clinical Effects of Glutamate Modulation in Schizophrenia$214,776
R21 · FY2014 · MH · contact PI
PET IMAGING OF GABAERGIC MODULATION$968
M01 · FY2005 · RR
DOPAMINE AND GABA IMAGING IN SCHIZOPHRENIA$176,409
K08 · FY2004 · MH
Raclopride/Tiagabine Study$1,666
M01 · FY2004 · RR
DOPAMINE AND GABA IMAGING IN SCHIZOPHRENIA$176,047
K08 · FY2003 · MH
DOPAMINE AND GABA IMAGING IN SCHIZOPHRENIA$170,972
K08 · FY2002 · MH
DOPAMINE AND GABA IMAGING IN SCHIZOPHRENIA$165,509
K08 · FY2001 · MH
DOPAMINE AND GABA IMAGING IN SCHIZOPHRENIA$160,831
K08 · FY2000 · MH